Publications

Publications

Comparison of low and intermediate source strengths for (125)I prostate brachytherapy implants.

By:
Contributors: Nawaid Usmani, MD, FRCPC, Sunita Ghosh, PhD
Brachytherapy. 2013 Sep-Oct;12(5):442-8. doi: 10.1016/j.brachy.2013.02.004. Epub 2013 May 23.

Abstract

PURPOSE:

To compare the implant quality and clinical outcomes for patients treated with low and intermediate strength (125)I seeds in prostate brachytherapy implants.

METHODS AND MATERIALS:

This retrospective review included 390 consecutive patients treated with prostate brachytherapy from 1999 to 2006. The first 142 patients were implanted with source strengths lower than 0.415U (0.327mCi), with the subsequent 248 patients implanted with source strengths higher than 0.493U (0.388mCi). Clinical, dosimetric, toxicity, and outcome data were compared between these two cohorts of patients.

RESULTS:

Despite having similar prostate volumes, fewer sources (median, 95 vs. 113; p<0.0001) and fewer needles (median, 23 vs. 29; p<0.0001) were implanted in the intermediate strength cohort. The postimplant dosimetry demonstrated better quality implants in patients treated with intermediate strength sources (median D90, 160.0Gy vs. 139.6Gy; p<0.0001), with greater dose inhomogeneity identified in the intermediate strength cohort of patients. A higher incidence of late rectal toxicity was identified in patients treated with intermediate strength sources despite lower rectal doses in this cohort. The biochemical relapse-free survival, prostate cancer survival, and overall survival were not significantly different between the two cohorts.

CONCLUSIONS:

The transition from low to intermediate strength sources has led to fewer resources being used and improved postoperative dosimetry. Although there were more rectal complications identified in the intermediate strength cohort of patients in this analysis, there were no other significantly worse clinical or biochemical outcomes for patients implanted with intermediate strength sources.

 

PubMed

Download PDF

Stay Informed

To stay up to date on all the latest news and publications, subscribe to our newsletter!

Lifestyle Management Program in Alberta – TrueNTH

The TrueNTH (pronounced True North) Lifestyle Management (LM) Program is part of the Global TrueNTH network funded by Movember (in partnership with Prostate Cancer Canada nationally). TrueNTH LM aims to improve the survivorship experience for men living with prostate cancer through physical activity, nutrition, and stress-reduction resources (programs and educational materials).

TrueNTH LM includes a free 12-week physical activity and yoga program with classes designed specifically to address the health and treatment related concerns for men living with prostate cancer. Men can also access a comprehensive online portal with tools, education, and home-based programming for help with staying active, reducing stress, and maintaining a proper diet.

In Calgary, TrueNTH LM has partnered with City of Calgary Recreation to offer programs at four different locations throughout the city. Registration is ongoing for men. In Edmonton, the Cancer Rehabilitation Clinic at the University of Alberta will be hosting a TrueNTH LM program starting in January 2016. Future programs will be announced as they become available. Men living in rural Alberta are able to join an online-based program at lifestyle.truenth.ca

All men who have been previously diagnosed with prostate cancer regardless of when they were diagnosed or what treatment they received can join the TrueNTH LM online portal or join a community program. Each person will undergo an initial health screening to ensure physical activity is safe.

For more information or to register, phone the Health and Wellness Lab in Calgary at .

Letter for participants

- Nicole Culos-Reed